Previous Chapter Chapter 11: Ketamine: The Pharmacokinetics and Pharmacodynamics in Misusing Populations Next Chapter

Kim Wolff

In: The SAGE Handbook of Drug & Alcohol Studies Volume 2

Chapter 11: Ketamine: The Pharmacokinetics and Pharmacodynamics in Misusing Populations

  • Citations
  • Add to My List
  • Text Size

Ketamine: The Pharmacokinetics and Pharmacodynamics in Misusing Populations
Ketamine: the pharmacokinetics and pharmacodynamics in medicinal and misusing populations
Kim Wolff
Ketamine

Ketamine (2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone) developed by Parke Davis laboratories in 1962 (Figure 11.1 and 11.2) is a dissociative general anaesthetic derivative of phencyclidine (PCP) available by prescription in the USA since the 1970s for human and veterinary use. Although its use had been thought is limited by emergent psychotomimetic episodes, ketamine is still widely used in acute, neuropathic and palliative care (Niesters et al., 2013; Teasell et al., 2010; Chizh, 2007; Huang et al., 2000; Lloyd-Williams, 2000). There is also growing enthusiasm for the use of ketamine to treat depression and suicidal ideation (Sassano-Higgins et al., 2016). Manufactured as a hydrochloride ketamine has also been utilized in dentistry ...

Looks like you do not have access to this content.

Login

Don’t know how to login?

Click here for free trial login.

Back to Top

Copy and paste the following HTML into your website